Why did GH outperform forecasts in 2024?

Guardant Health (GH) outperformed forecasts in 2024 due to several key factors:

1. **Strong Revenue Growth**: GH experienced a significant increase in total revenue, growing by 30.16%. This substantial growth is a testament to the company's successful market expansion and product adoption.
2. **Positive Earnings Momentum**: Despite a net loss of $111.01 million, the company showed a 40.65% year-over-year growth in net income. This indicates that GH is making progress towards profitability, which could have boosted investor confidence.
3. **Upcoming Products and Services**: GH's partnership with Bayshore HealthCare and the expansion of its cancer diagnostic tests into Canada suggest a strategic move towards market penetration. These partnerships could lead to increased demand for their services.
4. **Analyst Confidence**: Both Mizuho and Raymond James have given GH an "Outperform" rating, with Mizuho setting a price target of $55, indicating confidence in GH's growth potential. This positive analyst sentiment can attract more investors, increasing demand for the stock.
5. **Macroeconomic Factors**: The overall positive sentiment in the healthcare sector and the increasing demand for precision oncology services could have contributed to GH's outperformance.

In summary, GH's outperformance is likely a result of a combination of its strong revenue growth, positive earnings momentum, strategic partnerships, analyst confidence, and favorable macroeconomic conditions.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|GH|GH.O|Guardant Health|2024 Q1|13.890199426359025|30.90339823173858|27.6923076923077|185|
|GH|GH.O|Guardant Health|2024 Q2|-41.02870649022275|29.22712358731316|-25.373134328358198|185|
|GH|GH.O|Guardant Health|2024 Q3|-25.146918770760262|33.8712158288471|-20.547945205479458|185|
|GH|GH.O|Guardant Health|2024 Q4|40.65214950572863|30.157235543746047||185|